Genetic testing benefits for people diagnosed with fallopian tube, ovarian or primary peritoneal cancer
For women who have been diagnosed with fallopian tube, ovarian or primary peritoneal cancer, genetic testing may provide the following information and benefit:
- Your test results may make you eligible for treatment with a targeted therapy (e.g., PARP inhibitors) our a clinical trial.
- If you test positive for an inherited mutation in EPCAM, MLH1, MSH2, MSH6 or PMS2, you may be eligible for treatment with an immunotherapy agent.
- The test can help you understand your risk for a new cancer diagnosis and options for managing your risk.
- Your results can help your relatives understand their risk for cancer and take actions to stay healthy.